-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Group (01093.HK) announced that CRB-701 (SYS6002), which the group authorized CorbusPharmaceuticals, Inc. (Corbus) to develop, has been approved by the US Food and Drug Administration (FDA) to launch a registered clinical trial (trial code: TEMPO-1) for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC).

Zhitongcaijing·07/29/2026 12:41:24
Listen to the news
Zhitong Finance App News, Shiyao Group (01093.HK) announced that CRB-701 (SYS6002), which the group authorized CorbusPharmaceuticals, Inc. (Corbus) to develop, has been approved by the US Food and Drug Administration (FDA) to launch a registered clinical trial (trial code: TEMPO-1) for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC).